Integra LifeSciences Holdings Corporation (IART) News

Integra LifeSciences Holdings Corporation (IART): $55.96

0.99 (+1.80%)

POWR Rating

Component Grades













Filter IART News Items

IART News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IART News Highlights

  • For IART, its 30 day story count is now at 7.
  • Over the past 22 days, the trend for IART's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • BOLT are the most mentioned tickers in articles about IART.

Latest IART News From Around the Web

Below are the latest news stories about Integra Lifesciences Holdings Corp that investors may wish to consider to help them evaluate IART as an investment opportunity.

Integra's (IART) Q4 Earnings Top Estimates, Gross Margin Drops

Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.

Yahoo | February 24, 2022

Integra LifeSciences Holdings Non-GAAP EPS of $0.84 in-line, revenue of $405.5M beats by $2.09M

Integra LifeSciences Holdings press release (NASDAQ:IART): Q4 Non-GAAP EPS of $0.84 in-line. Revenue of $405.5M (+4.3% Y/Y) beats by $2.09M. For the first quarter 2022, the Company expects reported revenues in the range of $357 million to $365 million vs. consensus of $378.84M, representing reported growth of approximately -1% to...

Seeking Alpha | February 23, 2022

Integra LifeSciences (IART) Q4 Earnings and Revenues Surpass Estimates

Integra (IART) delivered earnings and revenue surprises of 1.20% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Integra LifeSciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides 2022 Financial Guidance

PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2021, consistent with its preliminary revenue results announced on January 11, 2022. Fourth Quarter 2021 Reported revenues were $405.5 million, representing an increase of 4.3% on a reported basis and an increase of 8.3% on an organic basis compared to the fourth quarter 2020. GAAP earnings per diluted

Yahoo | February 23, 2022

Should You Investigate Integra LifeSciences Holdings Corporation (NASDAQ:IART) At US$65.45?

Integra LifeSciences Holdings Corporation ( NASDAQ:IART ), is not the largest company out there, but it received a lot...

Yahoo | February 15, 2022

Integra LifeSciences: Time To Show Signs Of Life Again

A year ago, I concluded that Integra LifeSciences (IART) has seen a complete re-rating of its own valuation. Shares had seen a 50% return in just six months' time, as investors aggressively priced in the impact of interesting bolt-on M&A after a period in which shares were trading at compelling...

The Value Investor on Seeking Alpha | February 2, 2022

Integra LifeSciences Holdings (NASDAQ:IART) jumps 4.4% this week, though earnings growth is still tracking behind five-year shareholder returns

The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...

Yahoo | January 16, 2022

Integra LifeSciences Holdings to repurchase $125M shares

Integra LifeSciences Holdings (IART) enters into $125M accelerated share repurchase agreement at par value $0.01/share.The repurchase transactions are expected to be completed in the

Seeking Alpha | January 13, 2022

Integra (IART) Announces Preliminary Q4 & '21 Sales Results

Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.

Yahoo | January 13, 2022

Insights on the Veterinary Orthopedics Global Market to 2027 - Featuring Adobe Animal Hospital, BioMedtrix and Integra LifeSciences Among Others -

The "Veterinary Orthopedics Market Research Report by Product Type, by Application, by End-use, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to''s offering. The Global Veterinary Orthopedics Market size was estimated at USD 492.46 million in 2020, is expected to reach USD 536.39 million in 2021, and is projected to grow at a CAGR of 9.28% to reach USD 916.90 million by 2027. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive mer...

Benzinga | January 12, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.519 seconds.